(ACTUALITÉ EN BREF) AstraZeneca a lancé le Défi postdoctoral R&D 2023, qui invite les étudiants en dernière année de médecine et/ou de doctorat et les chercheurs postdoctoraux du monde entier à soumettre leurs propres propositions de recherche. L’initiative est conçue … Read the full press release
(IN BRIEF) AstraZeneca has launched the 2023 R&D Postdoctoral Challenge, which invites final-year MD and/or PhD students and postdoctoral researchers from around the world to submit their own research proposals. The initiative is designed to promote diversity of thought and … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of its acquisition of Neogene Therapeutics Inc. Neogene is a global clinical-stage biotechnology company that specializes in the discovery, … Read the full press release
(COMUNICADO DE PRENSA) CAMBRIDGE, 16-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueca farmacéutica y de biotecnología, ha anunciado la finalización de su adquisición de Neogene Therapeutics Inc. Neogene es una compañía global de biotecnología en etapa clínica que … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced that its drug Tezspire (tezepelumab) has been given the green light for self-administration by the European Medicine Agency’s Committee for Medicinal … Read the full press release
Posted in European Union, Healthcare, News, Pharma & Biotech, Science, Sweden, Technology, United Kingdom
Tagged allergic, asthma, asthma biologic, AstraZeneca, convenient pre-filled pen, EMA, eosinophilic, EU approval, Mene Pangalos, Professor Ian Pavord, self-administration, severe asthma patients, tezepelumab, Tezspire, University of Oxford
(COMUNICADO DE PRENSA) CAMBRIDGE, 13-Jan-2023 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), una multinacional británica-sueco-farmacéutica y biotecnológica, ha anunciado que su fármaco Tezspire (tezepelumab) ha recibido luz verde para la autoadministración por parte del Comité de Medicamentos de Uso Humano (CHMP) … Read the full press release
Posted in European Union, Healthcare, News, Pharma & Biotech, Science, Sweden, Technology, United Kingdom
Tagged alérgica, aprobación de la UE, asma, asma biológica, AstraZeneca, autoadministración, EMA, eosinofílica, Mene Pangalos, pacientes con asma grave, pluma precargada conveniente, profesor Ian Pavord, tezepelumab, Tezspire, Universidad de Oxford
(PRESS RELEASE) CAMBRIDGE, 2-Nov-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced fully funded postdoctoral research positions for the six winners at its R&D Postdoctoral Challenge announced earlier this year. The research positions … Read the full press release
(PRESSEMITTEILUNG) CAMBRIDGE, 2-Nov-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), ein britisch-schwedisches multinationales Unternehmen Pharma- und Biotechnologieunternehmen, hat voll finanzierte Postdoktoranden-Forschungsstellen für die sechs Gewinner in seinem R&D Postdoctoral Challenge früher in diesem Jahr angekündigt. Die Forschungspositionen werden für zwei Jahre … Read the full press release
Posted in Education, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Biopharmazie, Prof. Sir Mene Pangalos, R&D Postdoctoral Challenge
El desafío tiene como objetivo ayudar al descubrimiento de avances transformadores en las áreas de enfermedades centrales de AstraZeneca. Las propuestas exitosas asegurarán puestos de investigación posdoctorales totalmente financiados (COMUNICADO DE PRENSA) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), … Read the full press release
The challenge aims at helping the discovery of transformative breakthroughs across AstraZeneca’s core disease areas Successful proposals will secure fully funded postdoctoral research positions (PRESS RELEASE) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology … Read the full press release
(COMMUNIQUÉ DE PRESSE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON : AZN), une multinationale pharmaceutique et biotechnologique anglo-suédoise , a annoncé l’approbation par l’Union européenne (UE) de son médicament Saphnelo (anifrolumab) en tant que traitement d’appoint pour le traitement des patients … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced an European Union (EU) approval for its Saphnelo (anifrolumab) medicine as an add-on therapy for the treatment of adult patients with … Read the full press release
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, amyloid fibril deposits, amyloidosis, AstraZeneca, ATTR-CM, cardiomyopathies, Heart, heart failure, human monoclonal antibody, licence agreement, Marc Dunoyer, misfolded transthyretin, Neurimmune AG, NI006, rare disease, transthyretin amyloid cardiomyopathy
(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Aclidinium bromide, Adrian Kemp, Almirall S.A., AstraZeneca, biopharmaceutical, Bretaris, Brimica, Chronic obstructive pulmonary disease, Covis Pharma, Covis Pharma Group, dry powder inhaler, Duaklir, Eklira, formoterol, Genuair, inhaled respiratory medicines, LABA, LAMA, muscarinic antagonist, Tudorza
Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced it sold the global rights of its chronic obstructive … Read the full press release
Posted in Business, Healthcare, Management, News, Pharma & Biotech
Tagged Aclidinium bromide, Almirall S.A., Alvesco, AstraZeneca, biopharmaceutical, Bretaris, Chronic obstructive pulmonary disease, COPD, Covis Pharma, Covis Pharma Group, Duaklir, Eklira, formoterol, Genuair, Genuair device, global rights, inhaler, LABA, LAMA, long-acting beta2-agonist, long-acting muscarinic antagonist, medicines, Omnaris, Pressair, respiratory medicines, rights, Tudorza, Zetonna
(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its rare diseases arm Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences, Inc., a Clinical Stage … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abnormal antibody, acquisition, AL amyloidosis, Alexion, amyloids, AstraZeneca, bone marrow, CAEL-101, Caelum Biosciences, Cardiac Amyloid Reaching for Extended Survival, CARES Phase III clinical programme, defective plasma cells, IIIb disease, immunoglobulin, light chain (AL) amyloidosis, mAb, Marc Dunoyer, Mayo stage IIIa, monoclonal antibody, rare disease
(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive high-level results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abiraterone, AstraZeneca, Cancer, chemotherapy, Eastern Cooperative Oncology Group, EcoG, hormones, HRR, IDMC, Independent Data Monitoring Committee, Lynparza, mCRPC, MSD, MSD Research Laboratories, Olaparib, PARP, PROpel Phase III, prostate cancer, Roy Baynes, rPFS, Susan Galbraith
(PRESS RELEASE) CAMBRIDGE, 3-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced an agreement between the Company and the European Commission has been reached that puts an end of the legal proceedings over … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 2-Aug-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish science-led biopharmaceutical company, has announced that its Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus … Read the full press release
Posted in Healthcare, Marketing, News, Science, Technology, United Kingdom
Tagged AstraZeneca, bronchitis, corticosteroid, cough, cutaneous lupus erythematosus, Dr. Richard Furie, FDA, herpes zoster, infusion-related reactions, lupus, lupus nephritis, Mene Pangalos, MUSE Phase II trial, myositis, nasopharyngitis, OCS, oral corticosteroid, pathophysiology of lupus, Saphnelo, SLE, systemic lupus erythematosus, therapy, TULIP Phase III trials, type I IFN, type I interferon, upper respiratory tract infection
Increased efficacy with longer inter-dose interval Protection of over 70% starting after a first dose First indication of reduction in disease transmission of up to 67% (PRESS RELEASE) CAMBRIDGE, 3-Feb-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 14-Aug-2020 — /EuropaWire/ — Global science-led biopharmaceutical company AstraZeneca (LSE/STO/NYSE: AZN) has announced it signed an agreement with the European Commission (EC) for the supply of up to 400 million doses of the AZD1222 COVID-19 vaccine. Building … Read the full press release
ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years In pivotal ASCEND trial, 82% of patients with relapsed or refractory disease treated with Calquence remained progression … Read the full press release
(PRESS RELEASE) CAMBRIDGE, 5-Jun-2020 — /EuropaWire/ — British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca announced it will present new data across continuum of care from its broad renal portfolio during the 57th virtual congress of the European Renal Association – … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Society, United Kingdom
Tagged 57th European Renal Association, AstraZeneca, biopharmaceuticals, Chronic kidney disease, European Dialysis, Farxiga, FibroGen, haemodialysis, Hyperkalaemia, Lokelma, renal care, renal medicines, roxadustat, Ruud Dobber, Transplant Association
(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the second-largest pharmaceutical company in Japan Daiichi Sankyo (Daiichi Sankyo Company, Limited), has just been granted Orphan Drug Designation (ODD) in … Read the full press release
The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19 infection (PRESS RELEASE) CAMBRIDGE, 14-Apr-2020 — /EuropaWire/ — Pharmaceutical giant AstraZeneca to begin a randomised, global clinical trial to assess … Read the full press release
Posted in Healthcare, Science, Sweden, Technology, United Kingdom
Tagged assisted ventilation, AstraZeneca, best supportive care, blood cancers, Bruton’s tyrosine kinase, BSC, BTK, BTK inhibitor, CALAVI, Calquence, clinical trial, COVID-19, cytokine storm, exaggerated immune response, inflammatory cytokines, José Baselga, Louis M. Staudt M.D. Ph.D., lung disease
(PRESS RELEASE) CAMBRIDGE, 26-Mar-2020 — /EuropaWire/ — Science-led biopharmaceutical group AstraZeneca (LSE/STO/NYSE: AZN) has announced that its Lokelma (sodium zirconium cyclosilicate) is now approved in Japan. It is used for the treatment of patients with hyperkalaemia (elevated levels of potassium … Read the full press release
(PRESS RELEASE) BASEL, 6-Jan-2020 — /EuropaWire/ — ChemChina and Sinochem announce the creation of Syngenta Group. The new holding company is the consolidation of both companies’ agricultural assets. Mark Patrick, Chief Financial Officer (CFO) and member of the Syngenta Executive … Read the full press release
Posted in Agriculture, Business, Chemicals, Management, News, Switzerland
Tagged ADAMA, agriculture, appointment, AstraZeneca, ChemChina, Chen Lichtenstein, Erik Fyrwald, Mark Patrick, Sinochem, Syngenta, Syngenta Group
AstraZeneca / BenevolentAI artificial intelligence collaboration will accelerate drug discovery Potential new drugs discovery in the area of chronic kidney disease and idiopathic pulmonary fibrosis (PRESS RELEASE) CAMBRIDGE / LONDON, 30-Apr-2019 — /EuropaWire/ — New partnership, announced today, by AstraZeneca … Read the full press release
Posted in Artificial Intelligence (AI), Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI, AI discovery platform, artificial-intelligence, AstraZeneca, Benevolent Platform, BenevolentAI, biomedical knowledge graph, chemistry, Christina Malmberg Hägerstrand, Chronic kidney disease, CKD, clinical data, disease biology, genomics, Gonzalo Viña, idiopathic pulmonary fibrosis, IPF, Jennifer Hursit, Joanna Shields, Machine Learning, Matt Kent, Mene Pangalos, Michele Meixell, pathophysiology of disease, Rebecca Einhorn, Rob Skelding
27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukaemia New data on six medicines and potential new medicines across a variety of blood cancers demonstrate breadth of haematology portfolio … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged Acerta Pharma, AstraZeneca, biologics, blood cancer, haematology, hematology, leukaemia, lymphoma, MedImmune
CAMBRIDGE, 07-Nov-2018 — /EuropaWire/ — AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged Alvesco, asthma, AstraZeneca, Covis Pharma, Mark Mallon, Michael Porter, Omnaris, rhinitis, Zetonna
AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma CAMBRIDGE, 12-Sep-2018 — /EuropaWire/ — AstraZeneca and its partner Amgen Inc. (Amgen) … Read the full press release
Posted in Healthcare, Pharma & Biotech
Tagged Amgen, asthma, AstraZeneca, breakthrough therapy designation, eosinophilic_phenotype, medicine, respiratory, Sean Bohen, tezepelumab
Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent with previous trials AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, Cancer, Lynparza, Merck, Olaparib, ovarian_cancer
Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence of any remaining detectable cancer cells Phase III clinical trial results served as basis for recent US FDA regulatory submission … Read the full press release
Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo) CAMBRIDGE, 22-Feb-2018 — /EuropaWire/ — AstraZeneca and … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, Cancer, chemotherapy, Dave Fredrickson, Imfinzi, lung, lung cancer, lungcancer, MedImmune, radiation therapy, Scott J. Antonia MD Ph.D.
Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, Dave Fredrickson, inhibitor, Japan, Lynparza, Lynparza (olaparib), ovarian cancer, PARP, Roy Baynes
Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine to show superior PFS in this setting Data presented at the ESMO 2017 Congress follows FDA’s recent Breakthrough Therapy Designation … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, Dr. Luis Paz-Ares, Imfinzi, MedImmune, NSCLC, PACIFIC trial, Sean Bohen
Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent benefit across all subgroups, including patients with and without brain metastases Unprecedented median progression-free survival (PFS) of 18.9 months compared … Read the full press release
LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody (mAb) for the … Read the full press release
Qtern fixed-dose combination will provide an additional oral medicine option for patients taking Farxiga (dapagliflozin) to improve blood sugar level LONDON, 03-Mar-2017 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, Elisabeth Björk, FDA approval, Qtern, treatment of type-2 diabetes
STOCKHOLM, 27-Sep-2016 — /EuropaWire/ — New understanding of how hormone-producing cells in the pancreas decode their genetic instructions is pointing to novel targets for next generation medicines for type 2 diabetes, obesity and other metabolic disorders. A large scale analysis of … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
